| Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. RSS Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B ... N Engl J Med. 2018 Jan 11;378(2):113-125. 378 (2), 113-125, 2018 | 4527* | 2018 |
| Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. RM Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N ... N Engl J Med. 378 (24), 2288-2301, 2018 | 3421* | 2018 |
| Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial M Provencio, E Nadal, A Insa, MR García-Campelo, J Casal-Rubio, ... The Lancet Oncology 21 (11), 1413-1422, 2020 | 638 | 2020 |
| Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial K Nakagawa, EB Garon, T Seto, M Nishio, SP Aix, L Paz-Ares, CH Chiu, ... The Lancet Oncology 20 (12), 1655-1669, 2019 | 528 | 2019 |
| KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target M Román, I Baraibar, I López, E Nadal, C Rolfo, S Vicent, I Gil-Bazo Molecular cancer 17, 1-14, 2018 | 338 | 2018 |
| A prognostic DNA methylation signature for stage I non–small-cell lung cancer J Sandoval, J Mendez-Gonzalez, E Nadal, G Chen, FJ Carmona, ... Journal of clinical oncology 31 (32), 4140-4147, 2013 | 312 | 2013 |
| SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo S Mainardi, A Mulero-Sánchez, A Prahallad, G Germano, A Bosma, ... Nature medicine 24 (7), 961-967, 2018 | 306 | 2018 |
| A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic … S Popat, A Curioni-Fontecedro, U Dafni, R Shah, M O'Brien, A Pope, ... Annals of Oncology 31 (12), 1734-1745, 2020 | 241* | 2020 |
| Overall survival and biomarker analysis of neoadjuvant nivolumab plus chemotherapy in operable stage IIIA non–small-cell lung cancer (NADIM phase II trial) M Provencio, R Serna-Blasco, E Nadal, A Insa, MR García-Campelo, ... Journal of Clinical Oncology 40 (25), 2924-2933, 2022 | 202 | 2022 |
| Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis M Duruisseaux, A Martínez-Cardús, ME Calleja-Cervantes, S Moran, ... The Lancet Respiratory Medicine 6 (10), 771-781, 2018 | 189 | 2018 |
| Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma C Ambrogio, G Gomez-Lopez, M Falcone, A Vidal, E Nadal, N Crosetto, ... Nature medicine 22 (3), 270-277, 2016 | 188 | 2016 |
| Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes SM Dhanasekaran, O Alejandro Balbin, G Chen, E Nadal, ... Nature communications 5 (1), 5893, 2014 | 155 | 2014 |
| Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer—The ETOP NICOLAS … S Peters, E Felip, U Dafni, C Belka, M Guckenberger, A Irigoyen, E Nadal, ... Lung cancer 133, 83-87, 2019 | 153 | 2019 |
| Perioperative nivolumab and chemotherapy in stage III non–small-cell lung cancer M Provencio, E Nadal, JL González-Larriba, A Martínez-Martí, R Bernabé, ... New England Journal of Medicine 389 (6), 504-513, 2023 | 152 | 2023 |
| A novel serum 4-microRNA signature for lung cancer detection E Nadal, A Truini, A Nakata, J Lin, RM Reddy, AC Chang, N Ramnath, ... Scientific reports 5 (1), 12464, 2015 | 138 | 2015 |
| Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial V Subbiah, PA Cassier, S Siena, E Garralda, L Paz-Ares, P Garrido, ... Nature medicine 28 (8), 1640-1645, 2022 | 133 | 2022 |
| A novel epigenetic signature for early diagnosis in lung cancer. SDAJ Diaz-Lagares A, Mendez-Gonzalez J, Hervas D, Saigi M, Pajares MJ ... Clinical Cancer Research, 2016 | 132 | 2016 |
| KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma E Nadal, G Chen, JR Prensner, H Shiratsuchi, C Sam, L Zhao, ... Journal of Thoracic Oncology 9 (10), 1513-1522, 2014 | 131 | 2014 |
| A MicroRNA cluster at 14q32 drives aggressive lung adenocarcinoma E Nadal, J Zhong, J Lin, RM Reddy, N Ramnath, MB Orringer, AC Chang, ... Clinical cancer research 20 (12), 3107-3117, 2014 | 114 | 2014 |
| Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition C Pereira, P Gimenez-Xavier, E Pros, MJ Pajares, M Moro, A Gomez, ... Clinical Cancer Research 23 (12), 3203-3213, 2017 | 102 | 2017 |
Chiara AmbrogioProfessor, University of Turin在 unito.it 的电子邮件经过验证
